ltrasound-guided steroid injection and rehabilitation exercises to ease shoulder pain in women who have undergone surgery for breast cancer

Not Applicable

• Conditions: Subacromial pain syndrome without tendon lesions following surgery for breast cancer; Cancer

• Registration Number: ISRCTN10358568
• Lead Sponsor: Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-10-04
• Last Update Posted: 17 October 2022
• Study Completion: 2023-04-01

Recruitment & Eligibility

• Status: Ongoing
• Sex: Female
• Target Recruitment: 20

Inclusion Criteria

1. Aged 18 years old and over
2. Female gender
3. Surgery for breast cancer
4. Subacromial pain syndrome
5. Numerical Pain Rating Scale (NPRS) > 5
6. Signed informed consent

Exclusion Criteria

1. Allergies to triamcinolone or lidocaine
2. Severe thrombocytopenia (<10,000plt) or bleeding disorders
3. Chemotherapy or radiotherapy in progress
4. Metastatic disease
5. Shoulder tendon lesions
6. Cognitive impairment or psychiatric disorders
7. Pregnancy or breastfeeding

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Pain measured using the Numerical Pain Rating Scale at baseline (T0), after 1 week (T1), and after three months of follow-up (T2)

Secondary Outcome Measures

Name	Time	Method
<br> 1. Isometric muscle strength measured using the Hand Grip Strength test (HGS) (Jamar hydraulic hand dynamometer Sammons Preston, Rolyon, Bolingbrook, IL, USA) at baseline (T0), after 1 week (T1), and after three months of follow-up (T2)<br> 2. Shoulder function measured using the Oxford Shoulder Score (OSS) at baseline (T0), after 1 week (T1), and after three months of follow-up (T2)<br> 3. Quality of Life measured using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ - C30) at baseline (T0), after 1 week (T1), and after three months of follow-up (T2)<br> 4. Patient satisfaction measured using the Global Perceived Effect (GPE) scale, after 1 week (T1), and after three months of follow-up (T2)<br> 5. Safety measured using registering minor and major adverse events during the study period<br>